Cocrystal Pharma, Inc. - 8-K Filing Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2022 Annual Meeting of Stockholders held on May 18, 2022. Cocrystal Pharma, Inc. is a Delaware corporation with its principal executive offices in Bothell, WA, and its common stock trades on The Nasdaq Capital Market under the symbol COCP.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on corporate governance and stockholder voting outcomes.
Material Changes and Voting Results
Stockholders voted on four proposals. Proposals 1, 2, and 3 were approved, rendering Proposal 4 moot.
- Proposal 1 (Election of Directors): All five nominees were elected to one-year terms. Notable voting results included significant broker non-votes (19,336,908) across all nominees. Mr. Steven Rubin and Dr. Anthony Japour received the highest number of votes withheld.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the appointment of Weinberg & Company as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
- Proposal 3 (Reverse Stock Split): Stockholders approved an amendment to the Certificate of Incorporation to effect a reverse stock split of all outstanding common shares. The Board of Directors will determine the specific ratio within a range of one-for-four through one-for-12.
- Proposal 4 (Adjournment): This proposal to adjourn the meeting for further solicitation was not voted upon as sufficient votes were received to approve the other proposals.
Guidance, Outlook, and Risks
The filing does not contain management commentary on financial guidance, future outlook, or specific risk factors beyond the standard disclosure of the reverse stock split authorization. The approval of the reverse stock split indicates a strategic move to adjust the share structure, likely to meet listing requirements or improve marketability, though the specific ratio remains undetermined.
Investor Verification Checklist
- Verify the specific reverse stock split ratio once announced by the Board of Directors (range: 1-for-4 to 1-for-12).
- Review the definitive proxy statement filed on April 11, 2022, for detailed biographies of the newly elected directors and the rationale for the reverse split.
- Monitor subsequent filings for the effective date of the reverse stock split and the impact on share count and trading price.
- Confirm the continued appointment of Weinberg & Company as the auditor for the upcoming fiscal year.